Long course and prognostic factors of virus-induced cirrhosis of the liver.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  American Journal of Gastroenterology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8995940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term prognosis and prognostic factors of liver cirrhosis in the 1980s

  1994cited by this paper
• Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP).

  1994cited by this paper
• Hepatocellular carcinoma and viral cirrhosis.

  1994cited by this paper
• Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

  1993cited by this paper
• Prognostic indicators in compensated cirrhosis.

  1991cited by this paper
• Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients

  1990cited by this paper
• Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis

  1990cited by this paper
• Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

  1989cited by this paper
• [Hepatocellular carcinoma in cirrhosis. The surgeon's point of view].

  1989cited by this paper
• Cirrhotics with variceal hemorrhage: The importance of the time interval between admission and the start of analysis for survival and rebleeding rates

  1989cited by this paper
• Spontaneous bacterial peritonitis: An explosion of information

  1988cited by this paper
• Compensated cirrhosis: Natural history and prognostic factors

  1987cited by this paper
• Survival and prognostic indicators in compensated and decompensated cirrhosis

  1986cited by this paper
• Further report of a prospective randomized trial comparing distal splenorenal shunt with end-to-side portacaval shunt. An analysis of encephalopathy, survival, and quality of life.

  1985cited by this paper
• Prognostic Value of Total Serum Bilirubin/γ‐Glutamyl Transpeptidase Ratio in Cirrhotic Patients

  1984cited by this paper
• Latent portasystemic encephalopathy

  1981cited by this paper
• A 20-year prospective study of cirrhosis.

  1981cited by this paper
• Aspects of the natural history of gastrointestinal bleeding in cirrhosis and the effect of prednisone.

  1981cited by this paper
• Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

  1973cited by this paper
• Liver biopsy in the diagnosis of cirrhosis.

  1970cited by this paper
• Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease.

  1968cited by this paper
• Complications of diuretic therapy in hepatic cirrhosis.

  1966cited by this paper
• Treatment of hepatic coma by exchange blood transfusion.

  1966cited by this paper
• The neurological disorder associated with liver disease.

  1953cited by this paper

• Predicting Esophageal Varices in Liver Cirrhosis: The role of Platelet Count/Spleen Diameter Ratio

  2025cites this paper
• COMPARING THE PREDICTIVE EFFICACY OF MELD AND ALBI SCORES IN LIVER CIRRHOSIS PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING

  2025cites this paper
• Lobe-Based Hepatic Uptake Index of Gd-EOB-DTPA on Contrast-Enhanced MRI to Quantitatively Discriminate between Compensated and Decompensated Hepatitis B-Related Cirrhosis

  2024cites this paper
• Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

  2023cites this paper
• Emerging Therapeutic Targets for Portal Hypertension

  2023cites this paper
• The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile

  2022cites this paper
• Real-world outcomes of patients receiving prophylactic therapies for hepatic encephalopathy

  2021cites this paper
• Portal Hypertensive Ascites: Current Status

  2020cites this paper
• Social Impact of Hepatic Encephalopathy.

  2020cites this paper
• Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong

  2020cites this paper
• Epidemiology of Hepatic Encephalopathy.

  2020cites this paper
• Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany

  2020cites this paper
• Platelet Count/Splenic Diameter Ratio to Predict Oesophageal Varices in Portal Hypertension

  2019cites this paper
• Epstein-Barr virus infection is associated with a higher Child-Pugh score and may predict poor prognoses for patients with liver cirrhosis

  2019cites this paper
• Retrospective Study 5288 Safety of hepatitis B virus core antigen-positive grafts in liver transplantation: A single-center experience in China

  2019cites this paper
• Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis

  2019cites this paper
• Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.

  2019cites this paper
• Neurocritical Care Management of Hepatic Encephalopathy and Coma in Liver Failure

  2018cites this paper
• Current Diagnosis and Classification of Hepatic Encephalopathy.

  2018cites this paper
• The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies

  2018cites this paper
• Quality of life in patients with minimal hepatic encephalopathy

  2018cites this paper
• Diagnostic value of PIVKA-II in detecting hepatocellular carcinoma

  2017cites this paper
• Medical Management of Portal Hypertension and Its Complications

  2017cites this paper
• Preoperative Liver Recipient Evaluation and Preparation

  2017cites this paper
• Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.

  2017cites this paper
• Ultrathin disposable gastroscope for screening and surveillance of gastroesophageal varices in patients with liver cirrhosis: a prospective comparative study.

  2017cites this paper
• Cost‐effectiveness of elbasvir/grazoprevir use in treatment‐naive and treatment‐experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States

  2017cites this paper
• Clinical pathological correlation in 118 autopsy cases of cirrhosis of liver

  2016cites this paper
• The cost‐effectiveness of testing for NS5a resistance‐associated polymorphisms at baseline in genotype 1a‐infected (treatment‐naïve and treatment‐experienced) subjects treated with all‐oral elbasvir/grazoprevir regimens in the United States

  2016cites this paper
• Ratio of platelet count/spleen diameter predicted the presence of esophageal varices in patients with schistosomiasis liver cirrhosis

  2016cites this paper
• A study of platelet count/ spleen diameter ratio as a predictor of esophageal varices in patients of cirrhosis

  2016cites this paper
• Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.

  2015cites this paper
• Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon-α2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore

  2015cites this paper
• Platelet Count/Spleen Diameter Ratio, as a Non-Invasive Diagnosis of Esophageal Varices in Egyptian Patients with Liver Cirrhosis

  2015cites this paper
• State-of-the-art imaging of liver fibrosis and cirrhosis: A comprehensive review of current applications and future perspectives

  2015cites this paper
• The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis.

  2015cites this paper
• Computed tomography findings in liver fibrosis and cirrhosis.

  2014cites this paper
• Platelet count/spleen diameter ratio to predict esophageal varices in Mexican patients with hepatic cirrhosis.

  2014cites this paper
• Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

  2014cites this paper
• Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL

  2014cites this paper
• Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.

  2014cites this paper
• Angiogenic and anti-angiogenic factor gene transcript level quantitation by quantitative real time PCR in patients with hepatocellular carcinoma

  2013cites this paper
• Long-term combined therapy with very-low-dose peginterferon and ursodeoxycholic acid decreased the spleen size in a patient with hepatitis C virus-related cirrhosis.

  2013cites this paper
• Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal

  2013cites this paper
• Hepatic Encephalopathy: A Paradigm Shift

  2013cites this paper
• Title : Boceprevir for Previously Untreated Patients with Chronic Hepatitis C Genotype 1 Infection : A US-Based Cost-Effectiveness Modeling Study Short Title : Cost-Effectiveness Modeling Study of Boceprevir

  2013cites this paper
• Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

  2013cites this paper
• Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

  2013cites this paper
• Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy

  2013cites this paper
• Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

  2013cites this paper
• Incidence, etiology and mortality of cirrhosis: a population-based cohort study

  2012cites this paper
• PIN32 Economic Evaluation of Boceprevir for the Treatment of Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

  2012cites this paper
• Does this patient with liver disease have cirrhosis?

  2012cites this paper
• Université Victor Segalen Bordeaux 2

  2010cites this paper
• Clinical Significance of Genotypes and Precore/Basal Core Promoter Mutations in HBV Related Chronic Liver Disease Patients in North India

  2010cites this paper
• Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population

  2010cites this paper
• The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients

  2010cites this paper
• The epidemiology of cirrhosis and abnormal liver function in the general population of the UK

  2010cites this paper
• Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis.

  2009cites this paper
• Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.

  2009cites this paper
• Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality

  2009cites this paper
• External Validation of the Platelet Count/Spleen Diameter Ratio for the Diagnosis of Esophageal Varices in Hepatitis C Virus-Related Cirrhosis

  2009cites this paper
• Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy

  2009cites this paper
• MINISTÉRIO DA EDUCAÇÃO E DESPORTOS UNIVERSIDADE FEDERAL DE GOIÁS INSTITUTO DE PATOLOGIA TROPICAL E SAÚDE PÚBLICA

  2009cites this paper
• Liver-kidney pathophysiological interrelationships in liver diseases.

  2008influential citation
• Changing management and outcome of hepatocellular carcinoma: Evaluation of 501 patients treated at a single comprehensive center

  2008cites this paper
• When and how to scope in portal hypertension

  2008cites this paper
• Independent prognostic factors in patients with liver cirrhosis.

  2008cites this paper
• Bleeding index after the first course of endoscopic treatment for esophageal varices in liver cirrhotic patients with and without hepatocellular carcinoma.

  2007cites this paper
• Trace Element Concentration in Primary Liver Cancers—A Systematic Review

  2007cites this paper
• Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.

  2007cites this paper
• The cost‐effectiveness and budget impact of competing therapies in hepatic encephalopathy – a decision analysis

  2007cites this paper
• Non-invasive diagnosis of cirrhosis and the natural history of its complications.

  2007cites this paper
• The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.

  2006cites this paper
• Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

  2006cites this paper
• Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

  2006cites this paper
• Palliative care for patients with end-stage liver disease ineligible for liver transplantation.

  2006cites this paper
• Influence of recent advances in medical management on clinical outcomes of cirrhosis.

  2005influential citation
• Prophylaxie pré-primaire et hypertension portale : vers une prévention universelle de l'hypertension portale ?

  2005cites this paper
• Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up.

  2005cites this paper
• Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland

  2005cites this paper
• Hepatitis C Antibody Prevalence in the Insurance Population and in Applicants with Elevated Liver Enzymes

  2005cites this paper
• [When and how to evaluate the risk of a first variceal bleeding?].

  2004cites this paper
• [First episode of gastrointestinal bleeding, risk evaluation: when and how?].

  2004cites this paper
• Modelling the hepatitis C virus disease burden among injecting drug users in Scotland

  2004cites this paper
• Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma

  2004cites this paper
• An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis.

  2004cites this paper
• Cirrosis hep?tica

  2004cites this paper
• Hemodynamic derangement and cardiac dysfunction in cirrhosis.

  2004cites this paper
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  2004cites this paper
• Que doit-on faire pour prévenir les hémorragies par rupture de varices oesophagiennes ? - Quand et comment évaluer les risques d'une première hémorragie digestive ?

  2004cites this paper
• Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis.

  2004cites this paper
• HÉMORRAGIES DIGESTIVES

  2004cites this paper
• Prognostic Index of Cirrhotic Patients with Hepatic Encephalopathy with and Without Hepatocellular Carcinoma

  2004cites this paper
• An evidence-based approach to studies in cirrhosis and portal hypertension: medical management of mild to moderate ascites.

  2003cites this paper
• Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas.

  2003cites this paper
• Incidence and natural history of small esophageal varices in cirrhotic patients.

  2003cites this paper
• Evaluation and follow-up of patients with cirrhosis and oesophageal varices.

  2003cites this paper
• Severe Autoimmune Cytopenias in Treatment-Naive Hepatitis C Virus Infection: Clinical Description of 35 Cases

  2003cites this paper
• Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma?

  2002cites this paper